Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases
Conditions
Interventions
Intervention1:
Pumpkin seed
powder: 30 gm/day (15 gm before half an hour of breakfast
and 15 gm before half an hour of dinner) from
baseline till 3 months
Control Intervention1: Control(No
interventi
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Metabolic syndrome patients aged between 18-60 years 2. Metabolic Syndrome with three or more of the following five criteria is met: hyperglycemia, raised blood pressure, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, and central obesity [NCEP (ATP III)]. 3. Patient of either sex i.e., both male and female. 4. Patient willing to consent in writing
Exclusion criteria
Exclusion criteria: 1. Patient not willing to participate in the study 2. Aged less than 18 and more than 60years 3. Pregnant, nursing, or planning for pregnancy 4. Active medical condition- a known allergy or intolerance 5. Patient having any medical or surgical illness requiring priority management 6. Patient with other endocrinal diseases 7. Patient with Frank hepatorenal complication 8. Patient with chronic illness, congenital disorder, neurological and psychiatric disorder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Manage reduction of Fasting blood glucose and Post prandial glucose 2. Decrease HbA1c Timepoint: Glycaemic profile will be measured: First is at Baseline (at the time of patient enrollment) Second is Follow-up (after 12 weeks {3 months} of patient enrollment) | — |
Secondary
| Measure | Time frame |
|---|---|
| 3. Decrease Triglycerides, low-density lipoproteins Cholesterol, Total Cholesterol, Increase HDL 4. Decrease IL-6 (Interleukin-6), TNFa 5. Expression enhancement of Adiponectin levels & its gene expression due to alternative therapies (pumpkin seed powder)Timepoint: Anthropometric Measurements, Clinical parameters, Biochemical Parameters, genetic marker will be measured: First is at Baseline (at the time of patient enrollment) Second is Follow-up (after 12 weeks {3 months} of patient enrollment) | — |
Countries
India
Contacts
Public ContactDr Dileep Kumar Verma
King Georges Medical University
Outcome results
None listed